MG-132, an inhibitor of proteasomes and calpains, induced inhibition of oocyte maturation and aneuploidy in mouse oocytes

John B Mailhes*1, Colette Hilliard1, Mary Lowery2 and Steve N London1

Address: 1Department of Obstetrics and Gynecology Louisiana State University Health Sciences Center, P.O. Box 33932, Shreveport, Louisiana 71130 USA and 2Department of Pathology, Louisiana State University Health Sciences Center, P.O. Box 33932, Shreveport, Louisiana 71130 USA

E-mail: John B Mailhes* - jmailh@lsuhsc.edu; Colette Hilliard - chilli@lsuhsc.edu; Mary Lowery - mlower@lsuhsc.edu; Steve N London - slondo@lsuhsc.edu

*Corresponding author

Keywords: oocyte, chromosome, proteasome, MG-132

Abstract

Background: Although chromosome missegregation during oocyte maturation (OM) is a significant contributor to human morbidity and mortality, very little is known about the causes and mechanisms of aneuploidy. Several investigators have proposed that temporal perturbations during OM predispose oocytes to aberrant chromosome segregation. One approach for testing this proposal is to temporarily inhibit the activity of protein proteolysis during OM. We used the reversible proteasome inhibitor MG-132 to transiently perturb the temporal sequence of events during OM and subsequently analyzed mouse metaphase II (MII) for cytogenetic abnormalities. The transient inhibition of proteasome activity by MG-132 resulted in elevated levels of oocytes containing extra chromatids and chromosomes.

Results: The transient inhibition of proteasome-mediated proteolysis during OM by MG-I32 resulted in dose-response delays during OM and elevated levels of aneuploid MII oocytes. Oocytes exposed in vitro to MG-132 exhibited greater delays during metaphase I (MI) as demonstrated by significantly (p < 0.01) higher levels of MI arrested oocytes and lower frequencies of premature sister chromatid separation in MII oocytes. Furthermore, the proportions of MII oocytes containing single chromatids and extra chromosomes significantly (p < 0.01) increased with MG-132 dosage.

Conclusions: These data suggest that the MG-I32-induced transient delay of proteasomal activity during mouse OM in vitro predisposed oocytes to abnormal chromosome segregation. Although these findings support a relationship between disturbed proteasomal activity and chromosome segregation, considerable additional data are needed to further investigate the roles of proteasome-mediated proteolysis and other potential molecular mechanisms on chromosome segregation during OM.

Background

Although numerous hypotheses have been proposed to describe the etiology of aneuploidy in human gametes, the only steadfast association remains maternal age [1,2]. Besides this association, very little information is available about the numerous potential mechanisms that may
disrupt normal chromosome segregation in oocytes. Based on studies involving compounds that alter microtubular kinetics and induce both cell-cycle delay and aneuploidy, several groups have proposed that temporal perturbations during mammalian oocyte maturation (OM) predispose oocytes to aneuploidy [3–6]. In addition to faulty microtubule kinetics, perturbations during OM may also stem from abnormal function of centrosomes, kinetochores, spindle checkpoints proteins, the anaphase-promoting complex (APC), the securin-separin-cohesion complex proteins, and the proteasome [7].

OM encompasses the nuclear and cytoplasmic changes that occur during the transition from the dictyotene stage of meiosis I to metaphase II (MII). During this transition, tightly-regulated post-translational phosphorylation-dephosphorylation events and proteasome-mediated proteolytic reactions regulate the activation and inactivation of signal transduction pathways that control chromatin condensation, nuclear membrane dissolution, microtubule nucleation, and formation of a haploid oocyte [8–10]. Several kinases that exert major roles during OM include maturation promoting factor (MPF) [9,11], mitogen-activated protein kinases (MAPKs) [12,13], and the product of the c-mos protooncogene Mos kinase [14,15]. Also, during OM oocytes undergo two highly-regulated metaphase-anaphase transitions (MAT) in which homologous chromosomes are equally and randomly segregated to an oocyte and first polar body and a subsequent division in which equational division of sister chromatids results in a haploid oocyte and a second polar body. The MATs are predicated upon the coordinated activities of the spindle checkpoint [16,17], the anaphase-promoting complex (APC) or cyclosome [18,19], the proteasome [20,21], and the cohesion-complex proteins involved with chromosome cohesion and separation [22–24]. Alterations in the temporal sequence of these coordinated activities may potentially predispose cells to faulty chromosome segregation.

Abnormal chromosome segregation has been observed in mice lacking the Mad2 checkpoint protein [25]. The spindle checkpoint utilizes sensory proteins that detect kinetochore-microtubule tension and occupancy and transiently block anaphase until all of the chromosomes are properly attached to microtubules [16,26,27]. Although the mammalian spindle checkpoint appears to differ between mitosis and meiosis, the two meiotic divisions, and male and female germ cells [28], anaphase subsequently follows stable kinetochore-microtubule attachments [17,29] in both vertebrate mitotic [30] and meiotic [31] cells.

The APC is a large protein complex that ubiquinates mitotic cyclins and other regulatory proteins that are destined for timely proteolysis by proteasomes [10,20]. Proteasomes are multicatalytic 26S proteases consisting of a 20S central core catalytic subunit bordered by two 19S components [32,33] which hydrolyze C-terminal peptide bonds to acidic, basic, and hydrophobic amino-acid residues [20,34]. Proteasomes proteolyze securins which inhibit separase activity. Separase is needed for inactivating cohesion and enabling sister chromatid separation [35–37] in both fission yeast [38] and mammalian cells [39]. Although differences have been reported among species [40] and cell types [41], it appears that the majority of cohesion is removed from mammalian chromosomes during prophase and prometaphase; whereas, a lesser amount remains at kinetochores until anaphase onset. Proteasomes translocated to meiotic spindles of rat oocytes and MG-132 induced-inhibition of proteasomal activity resulted in partial segregation of chromosomes during meiosis I [42]. Moreover, defective proteasomal activity in fission yeast impaired chromosome segregation [38].

To test the hypothesis that transient inhibition of proteosomal activity during mouse meiosis I was associated with chromosome missegregation, mouse oocytes were exposed in vitro to the reversible proteasome inhibitor MG-132 and metaphase II (MII) oocytes were analyzed for structural and numerical chromosome aberrations. This transient arrest of proteasomal activity represents a perturbation during the normal temporal sequence of events during OM.

**Results**

Transient exposure of mouse oocytes to MG-132 for 6 h followed by washout of the compound and an additional 17 h culture in vitro enabled exposure of cells during meiosis I and sufficient time for them to progress to metaphase II. Although the majority of MII oocytes were classified as normal (Fig. 1A), the data indicated that MG-132 induced a dose-response perturbation or delay in the rate of OM and an increase of single, unpaired chromatids and hyperploidy in MII oocytes (Table 1I). The significant (P < 0.01) increase in the proportion of MII oocytes (Fig. 1B) in the 10.0 mcg/ml group relative to the other groups and the significant (P < 0.01) decrease of oocytes exhibiting premature centromere separation (PCS) (Fig. 1C) in the 10.0 mcg/ml group relative to the controls suggest that proteasomal inhibition retarded the rate of OM. An inverse relationship has been shown to exist between the proportions of arrested MI oocytes and MII oocytes exhibiting PCS [43]. The significant (P < 0.01) dose responses of higher frequencies of MI oocytes with single chromatids (Figs. 1C,1E) and of hyperploidy (Figs. 1D,1E) suggest that the MG-132-induced transient inhibition of proteasomal and calpain activities during meiosis I predisposed oocytes to abnormal chromosome segregation.
When oocytes were continuously exposed to 0.0, 0.5, 5.0, 25.0 or 50.0 µg/ml MG-132 from one h after initiating the culture until 17 h later, the proportions of MI arrested oocytes were 5.7% (5/87), 12.3% (14/114), 39.3% (44/112), 100% (98/98), and 100% (91/91), respectively. Of the MI oocytes in the 25.0 and 50.0 µg/ml MG-132 groups, 68.2% (30/44) and 100% exhibited diffuse chromatin (Fig. 1F); whereas, those oocytes continuously exposed to 0.0, 0.5 or 5.0 µg/mlMG-132 did not display diffuse chromatin. Additionally, the proportions of MI oocytes displaying homologue separation (Figs. 1G,1H) in oocytes transiently exposed to MG-132 for 6 h were 0% (0/13), 0% (0/19), 11.5% (3/26), 15.1% (8/53), respectively for 0.0, 5.0, 7.5, and 10.0 µg/mlMG-132. Oocytes with premature anaphase, polyploidy, or structural chromosome aberrations were not found.

**Discussion**

Proteasome activity is required for germinal vesicle breakdown (GVBD) in starfish and toad oocytes [44,45] and for activating Xenopus oocytes [45,46]. Also, proteasomes are needed for regulating centrosome segregation [38,47], kinetochore structure [39], and sister chromatid cohesion and separation [48]. When rat oocytes were exposed to the proteasome inhibitor MG132, proteasomes translocated to the meiotic spindle, MPF activity was sustained, and oocytes were arrested in MI with partially segregated chromosomes [42].

Besides inhibiting proteasome activity, the peptide aldehide proteasome inhibitors have been also reported to repress certain lysosomal cysteine proteases and calpains [49]. The finding that MG-132 can obstruct the casein degrading activity of the calcium-dependent protease calpain [50] appears relevant to oocyte maturation. Calpain activity is needed for proteolysis of the c-mos proto-oncogene product pp39 mos in Xenopus oocytes [51], certain cytoskeletal proteins (alpha-tubulin, actin, dynamin, lamin B) in starfish oocytes [52], and of cyclin in Xenopus egg extracts [53].

We report that exposure of mouse oocytes to 10.0 mcg/ml MG-132 during meiosis I led to significant (P < 0.01) increases in the proportions of MI arrested oocytes and of MII oocytes with SC and hyperploidy. Coupled with these findings was a significant (P < 0.01) decrease in the incidence of MII oocytes exhibiting PCS (Table 1). Chemical induction of MI arrest in mammalian oocytes and spermatocytes indicates cell cycle retardation which is often associated with aneuploidy [43,54]. Although 10.0 mcg/ml MG-132 increased the frequency of MI arrested oocytes, this cell-cycle retardation may not be entirely attributed to proteasome inhibition. MG-132 can also inhibit calpains [50] which are needed for cell cycle progression [52] and of cyclin in Xenopus egg extracts [53]. Previous studies [5,55] have shown that an inverse relationship usually exists between the proportions of arrested MI oocytes and MII oocytes exhibiting PCS. Oocytes residing in MII for longer periods of time tend to display higher frequencies of PCS; whereas, those deferred in MI spend less time in MII prior to fixation. The significant (P < 0.01) increase in the proportions of MII oocytes exhibiting PCS in controls relative to the 10.0 µg/ml group reflects the greater length of time that control oocytes spent in MII prior to fixation. We suggest that the PCS detected in MII

**Figure 1**

Cytogenetic analysis of mouse oocytes following in vitro exposure to MG-132, chromosome configurations are shown. (A) metaphase II oocyte, normal, n = 20 dyads. (B) metaphase I oocyte, normal, N = 20 tetrads. (C) metaphase II oocyte, hypoploidy, premature centromere separation (incomplete), n = 19 1/2 (10 dyads and 19 chromatids), arrow points to one of the 19 single, unpaired chromatids. (D) metaphase II oocyte, hyperploidy, n = 22 dyads. (E) metaphase II oocyte, hyperploidy, single-unpaired chromatid, n = 20 1/2 (20 dyads and one single, unpaired chromatid indicated by arrow). (F) metaphase I oocyte, diffuse chromatin, N= 20 probable tetrads. (G) metaphase I oocyte, homologue separation, N= 20 (17 tetrads and 6 dyads), arrow points to one of the 6 dyads. (H) metaphase I oocyte, homologue separation, N= 19 1/2 (16 tetrads and 7 dyads).
oocytes mainly resulted from in vitro aging. As such, the frequencies of PCS noted in Table 1 would represent independent events relative to the other cytogenetic abnormalities reported.

On the other hand, PCS during meiosis I can result in aneuploid MII oocytes. PCS of homologous chromosomes and sister chromatids prior to establishing proper kinetochore-spindle attachment during meiosis I increases the probabilities of both homologues going to the same pole and of equational division of sister chromatids during anaphase I. Upon normal fertilization, MII oocytes with an additional chromosome result in trisomic zygotes; whereas oocytes containing an extra chromatid would be expected to produce 50% trisomic zygotes due to random segregation during anaphase II. This situation also applies to oocytes missing chromosomes and chromatids. Experimental data support PCS as a prelude to aneuploidy. PCS of homologues during meiosis I and equational division of sister chromatids during anaphase I [56,57] and premature separation of chromatids during mitosis [60,61] have been shown to increase the incidence of aneuploidy in subsequent divisions. The partially segregated chromosomes found in rat oocytes exposed to MG-132 may have represented homologous chromosomes and/or sister chromatids [42].

Although the frequency of homolog separation increased with MG-132 dose, the sample size of 11 oocytes is much too low to comment about their possible origin or their influence on other abnormalities detected in MII oocytes. The possibility exists that the observed homolog separation may actually reflect anaphase onset. The finding of diffuse chromatin in MII oocytes continuously exposed to 25.0 and 50.0 μg/mlMG-132 may be related to the sustained elevation of MPF activity noted in rat oocytes exposed to MG-132 [42] and the stabilization of polyubiquitinated proteins and enhanced deubiquitination of nucleosomal histones in chromatin following proteasomal inhibition [62].

Conclusions
The findings of the present study indicate that transient in vitro exposure of mouse oocytes to MG-132 is associated with abnormal chromosome segregation. However, additional data are clearly needed to further investigate the roles of calpain proteolysis and proteasome-mediated proteolysis on chromosome segregation as well as the numerous other potential molecular mechanisms of aneuploidy.

Methods

Animals
Female, ICR (Harlan Sprague-Dawley, Indianapolis, IN) mice between 26–33 g (8–12 wks of age) were used in all experiments. They were housed under ambient temperature of 21–23°C, relative humidity of 50–5%, and a 12-h light/12-h dark photoperiod. Feed and water were provided ad libitum. This research was approved by the Louisiana State University Health Sciences Center Animal Resources Advisory Committee.

Oocyte collection, culture and exposure to MG-132
For each replicate experiment, five similarly treated mice received an intraperitoneal injection of 7.5 IU pregnant mare serum gonadotrophin (Dr. A.F. Parlow, National Hormone & Peptide Program, Torrance, CA) to augment the number of maturing follicles. Forty-six h later, the mice were euthanized by CO₂ inhalation and their reproductive tracts placed into Waymouth culture medium.

Table 1: Cytogenetic analysis of mouse metaphase II oocytes following in vitro exposure to the proteasome inhibitor MG-132

| MG-132 (mcg/ml) | No. cells analyzed | No. MI oocytes (%) | No. MII oocytes (%) | No. premature centromere separation (%) | No. single chromatids (%) | No. haploid (%) | No. hypoploid (%) | No. hyperploid (%) |
|----------------|-------------------|--------------------|-------------------|----------------------------------------|--------------------------|----------------|-----------------|------------------|
| Control        | 130               | 13 (10.0)a         | 117 (90.0)        | 43 (36.8)a                              | 1 (0.9)a                 | 101 (86.3)    | 16 (13.7)       | -0-              |
| 5.0            | 158               | 19 (12.0)a         | 139 (88.0)        | 38 (27.3)                               | 3 (2.2)b                 | 121 (87.1)    | 18 (12.9)       | -0-              |
| 7.5            | 191               | 26 (13.6)a         | 165 (86.4)        | 44 (26.7)                               | 11 (6.7)b                | 142 (86.1)    | 18 (10.9)       | 5 (3.0)b         |
| 10.0           | 125               | 53 (42.4)b         | 72 (57.6)         | 13 (18.1)b                              | 11 (15.3)c               | 62 (86.1)     | 3 (4.2)         | 7 (9.7)c         |

Different superscripts among proportions in the same column indicate significant (P < 0.01) differences.
MG-132 is a peptide aldehyde that inhibits ubiquitin-mediated proteolysis by binding to and inactivating 20S and 26S proteasomes [49,62]. Although 1–10 μM MG-132 inhibited first polar body extrusion in rat oocytes, its activity is reversible [42]. We conducted preliminary experiments to obtain a MG-132 dose range that would transiently perturb or inhibit OM during meiosis I while enabling oocytes to complete OM following washing out of the compound. Data from oocytes cultured in either 0.0, 0.5, 5.0, 25.0, or 50.0 μg/ml MG-132 from one h after initiating the culture until 6 h later when the chemical was washed out (4X) and cultured for an additional 17 h in media without MG-132, oocytes exposed to 25.0 and 50.0 μg/ml MG-132 were still arrested in MI. On the other hand, when oocytes were exposed to these same MG-132 doses from one h after initiating the culture until 6 h later when the chemical was washed out (4X) and cultured for an additional 17 h in media without MG-132, oocytes exposed to 25.0 and 50.0 μg/ml MG-132 were still arrested in MI. Thus, data from these preliminary experiments enabled the selection of a protocol in which oocytes were placed into complete culture media and incubated for 1 h prior to adding either 0 (solvent only), 5.0, 7.5, or 10.0 μg/ml MG-132. Six h later, the MG-132 was washed out of the media by rinsing the oocytes four times in complete media without MG-132 and then re-incubated for 17 h. Under this protocol, oocytes were exposed to MG-132 during meiosis I and the subsequent 17 h culture time provided sufficient time for the oocytes to overcome the MG-132-induced meiotic block and progress to MII. Control oocytes were cultured in 7.5 μl DMSO per ml complete media and processed in the same manner as those exposed to MG-132.

**Cytogenetic analysis and statistical analysis of data**

Oocytes were collected and processed according to a mass-harvest procedure [63] and chromosomes were C-banded [64] to distinguish between complete dyads (MII chromosomes) and disjoined dyads (single chromatids). In each cell analyzed, the number of chromosomes and/ or chromatids was counted at 1000 × magnification to provide data for calculating aneuploidy. The number of hypoploid (n = 10–19 1/2), haploid (n = 20), hyperploid (n = 20 1/2–29 1/2), and polyploid (n = 30–40) MII oocytes were recorded. An oocyte classified as 20 1/2 contains 20 dyads and one chromatid or one-half dyad. The frequencies of each ploidy class were divided by the total number of MII oocytes analyzed excluding polyploidy. The frequencies of MII oocytes displaying premature centromere separation (PCS), single chromatids (SC), premature anaphase (PA) were also calculated relative to the total number of MII oocytes analyzed. Since MII and polyploid oocytes are distinct categories and are disregarded when computing aneuploidy, their frequencies were calculated relative to the total number of oocytes analyzed. The criteria for eliminating a cell from analysis included: inadequate C-banding for discriminating between intact dyads and those separated at the centromere, overlapped or clumped chromosomes, or excessive chromosome scatter that precluded an objective analysis of numerical or structural aberrations. The frequencies of hyperploid cells were used as a measure of aneuploidy because an unknown proportion of the hypoploid cells is influenced by technical artifact resulting from excessive chromosome scatter during slide preparation. Chi-Square analysis and the Fisher’s Exact Test were used for data analyses.

**Author’s contributions**

Each author contributed substantially to the various aspects required for the timely completion of this study. Their respective efforts are reflected by the order of authorship.

**References**

1. EB Hook: Maternal age, paternal age, and human chromosome abnormality: nature, magnitude, etiology, and mechanisms of effects. In: Aneuploidy: Etiology and Mechanisms (Edited by: Delarco VL, Voytek PE, Hollyaerder A) New York, Plenum Press 1985, 117-132.
2. Hassold T, Sherman S: The origin of non-disjunction in humans. In: Chromosomes Today (Edited by: Summer A, Chandley AC) London, Chapman and Hall 1993, 11:313-322.
3. Hansmann I, Pabst B: Nondisjunction by failures in the molecular control of oocyte maturation. Ann Anat 1992, 174:485-490.
4. Eichenlaub-Ritter U: Studies on maternal age-related aneuploidy in mammalian oocytes and cell cycle control. In: Chromosomes Today (Edited by: Summer AT, Chandley AC) London, Chapman & Hall 1993, 11:323-336.
5. Mailhes JB, Marcheti F: The influence of postovulatory ageing on the retardation of mouse oocyte maturation and chromosome segregation induced by vinblastine. Mutagenesis 1994, 9:541-545.
6. Pichot M: The human oocyte. Genetic aspects. Ann. Genet 1997, 40(1):15-120.
7. Nasmyth K: Disseminating the genome: joining, resolving, and separating sister chromatids during mitosis and meiosis. Annu Rev Genet 2001, 35:673-745.
8. Bornslaeger EA, Mattei P, Schultz RM: Involvement of cAMP-dependent protein kinase and protein phosphorylation in regulation of mouse oocyte maturation. Dev Biol 1986, 114:453-462.
9. Dekel N: Protein phosphorylation-dephosphorylation in the meiotic cell cycle of mammalian oocytes. Rev Reprod 1996, 1:82-88.
10. Kotani S, Tanaka H, Yasuda H, Todokoro K: Regulation of APC activity by phosphorylation and regulatory factors. J Cell Biol 1999, 146:791-800.
11. Downs SM, Daniel SAJ, Bornslaeger EA, Hoppe PC, Eppig JJ: Maintenance of meiotic arrest in mouse oocytes by purines: modulation of APC activity. Gamete Res 1989, 23:323-334.
12. Moos J, Visconti PW, Moore GD, Schultz RM, Kopf GS: Potential role of mitogen-activated protein kinase (MAP) in pronuclear envelope assembly and disassembly following fertilization of mouse eggs. Biol Reprod 1995, 53:692-699.
13. Murray AW: MAP kinases in meiosis. Cell 1998, 92:157-159.
14. Paules RS, Bucicorne R, Moschel RC, Vande Woude GF, Eppig JJ: Mouse mos protooncogene product is present and functions required for anaphase and cytokinesis in human cells. Mol Biol Cell 1998, 9:1379-1385.
15. Hashimoto N: Role of c-mos proto-oncogene product in the regulation of mouse oocyte maturation. Horm Res 1996, 46:11-14.
16. Anon A: The spindle checkpoint. Curr Opin Genet Develop 1999, 9:13-15.
17. Howell BJ, Hoffman DB, Fang G, Murray AW, Salmon ED: Visualization of Mad2 dynamics at kinetochores, along spindle fibers, and at spindle poles in living cells. J Cell Biol 2000, 150:1233-1250.
18. Page AM, Hieter P: The anaphase-promoting complex: new partners and regulators. Annu Rev Biochem 1999, 68:583-609.
19. Nasmyth K, Peters JM, Uhlmann F:Mad2. The spindle checkpoint: cutting the ties that bind sister chromatids. Science 2000, 288:1379-1385.
20. Glickman MH, Ciechanover A: Functions of the proteasome: the lysis at the end of the tunnel. Nature 2001, 408:268-274.
21. Jospefsberg LBY, Galiani D, Dantes A, Amsterdam A, Dekel N: The proteasome is an essential mediator of the activation of pre-MPF during starfish oocyte maturation. Biomed Biophys Res Commun 1997, 236:40-43.
22. Zou H, McGarry T, Bernal T, Kirschner MW: Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 1999, 285:418-422.
23. Lee DH, Goldberg AL: Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998, 8:397-403.
24. Tsubuki S, Saito Y, Tomioka M, Ito H, Kawashima S: Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. Biochim Biophys Acta 1996, 119:572-578.
25. Watanabe N, Vande Woude G, Ikawa Y, Sagata N: Specific proteolysis of the c-mos proto-oncogene product by calpain during fertilization of Xenopus eggs. Nature 1989, 342:505-511.
26. Santella L, Kyozuka K, Hoving S, Munchbach M, Quadrani M, Daines P, Zamparelli C, James P, Carafoli E: Defects in components of the proteasome enhance transcriptional silencing at fission yeast centromeres and impair chromosome segregation. Mol Cell Biol 1999, 19:5155-5165.
27. Uhlmann F: Secured cutting: controlling separase at the metaphase to anaphase transition. EMBO reports 2001, 2:487-492.
28. Darwiche N, Freeman LA, Strunnikov A: Characterization of the components of the putative mammalian sister chromatid cohesion complex. Gene 1999, 233:39-47.
29. Van Heemst D, Heyting C: Sister chromatid cohesion and recombination in mammalian cells. Trends Biochem Sci 1996, 21:56-59.
30. Todd K, Dillingham M: C-mos is required for anaphase and cytokinesis in human cells. Proc Natl Acad Sci U S A 1997, 94:5395-5399.
31. Pines J: Role of cyclin B degradation in the metaphase to anaphase transition of meiosis in rat oocytes. Biochim Biophys Res Commun 1994, 38:310-317.
32. Sawada M, Kyozuka K, Morinaga C, Iizumi K, Sawada H: The proteasome is an essential mediator of the activation of pre-MPF during meiosis of starfish oocytes and zygotes. Dev Biol 1999, 213:555-567.
33. Page AM, Hieter P: The anaphase-promoting complex: new partners and regulators. Annu Rev Biochem 1999, 68:583-609.
34. Nasmyth K, Peters JM, Uhlmann F: Splitting the chromosome: cutting the ties that bind sister chromatids. Science 2000, 288:1379-1385.
35. Glickman MH, Ciechanover A: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002, 82:373-428.
36. Glickman MH, Ciechanover A: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002, 82:373-428.
37. Amon A: The spindle checkpoint. Cell 2000, 101:715-726.
38. Ciechanover A, Kelly LA, Alejandro M, Lipps HJ: The ubiquitin pathway: destruction for the sake of construction. J Biol Chem 2000, 275:17039-17042.
sequent segregation of homologues and chromatids in mammalian oocytes
Hum Reprod 1995, 10:2350-2360
58. Mailhes JB, Young D, London SN: 1,2-Propanediol-induced premature centromere separation in mouse oocytes and aneuploidy in one-cell zygotes. Biol Reprod 1997, 57:92-98
59. Mailhes JB, Young D, London SN: Postovulatory ageing of mouse oocytes in vivo and premature centromere separation and aneuploidy. Biol Reprod 1998, 58:1206-1210
60. Fitzgerald PH, Pickering AF, Mercer JM, Mietheke PM: Premature centromere division: A mechanism of non-disjunction causing X chromosome aneuploidy in somatic cells of man. Ann Hum Genet 1975, 38:417-428
61. Gabarron J, Jimenez A, Glover G: Premature centromere division dominantly inherited in a subfertile family. Cytogenet Cell Genet 1986, 43:69-71
62. Rock KL, Gramm C, Rochstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL: Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994, 78:767-771
63. Mailhes JB, Yuan ZP: Cytogenetic technique for mouse metaphase II oocytes. Gamete Res 1987, 18:77-83
64. Salamanca F, Armendares S: C-bands in human metaphase chromosomes treated by barium hydroxide Ann Genet 1974, 17:135-136

Publish with BioMed Central and every scientist can read your work free of charge

"BioMedcentral will be the most significant development for disseminating the results of biomedical research in our lifetime."

Paul Nurse, Director-General, Imperial Cancer Research Fund

Publish with BMC and your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours - you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/manuscript/
editorial@biomedcentral.com